You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

158 Results
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Intent: Palliative
Jun 2021
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Palliative
Funding:
Exceptional Access Program
    crizotinib - First or second-line treatment for ALK-positive advanced NSCLC, according to specific criteria
Exceptional Access Program
    crizotinib - First-line treatment for ROS1-positive locally advanced (not amenable to curative therapy) or metastatic NSCLC, according to specific criteria
Mar 2021
Regimen
Cancer Type:
Genitourinary, 
Testis
Intent: Curative
Mar 2021
Regimen
Cancer Type:
Gynecologic, 
Endometrial
Intent: Adjuvant, Palliative
Aug 2021
Regimen
Cancer Type:
Gynecologic, 
Endometrial
Intent: Palliative
Funding:
ODB - General Benefit
  • megestrol - oral tablets
Oct 2017
Regimen
Cancer Type:
Gynecologic, 
Ovary
Intent: Adjuvant
Jun 2021
Regimen
Cancer Type:
Gynecologic, 
Ovary
Intent: Palliative
Oct 2017
Regimen
Cancer Type:
Gynecologic, 
Ovary
Intent: Palliative
Aug 2021
Regimen
Intent: Palliative
Oct 2017
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Intent: Palliative
Funding:
ODB - General Benefit
  • cyclophosphamide - oral tablets
New Drug Funding Program
  • Bortezomib - Relapsed or Refractory Multiple Myeloma
ODB - General Benefit
  • prednisone
Apr 2021
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's High Grade, 
Lymphoma - Non-Hodgkin's Intermediate Grade
Intent: Palliative, Curative
Funding:
ODB - General Benefit
  • prednisone
Oct 2017

Pages